Charu Aggarwal

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figure S3 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

  2026-06-17

• Supplementary Figure S2 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

  2026-06-17

• Supplementary Table S1 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

  2026-06-17

• Supplementary Figure S1 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

  2026-06-17

• An EHR-embedded SmartForm (OncAssessment) paired with ePROs to enable real-time structured documentation of key oncologic data during routine cancer care: A pragmatic implementation study.

  Journal of Clinical Oncology · 2026-05-28

• From plenary to practice: A large language model (LLM)–based thematic analysis of landmark clinical trial discussions and factors influencing their real-world adoption.

  Journal of Clinical Oncology · 2026-05-27

• Illusion of Comprehensive Testing in Non–Small Cell Lung Cancer: Why Coverage, Sensitivity, and Reporting Matter

  JCO Oncology Practice · 2026-04-22

• Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort study

  Frontiers in Oncology · 2026-04-22

• Supplementary Tables S1-S3 from Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  2025-11-25

• A United States-Based Real-World Study on Biomarker Testing and Rebiopsy Rates Among Patients With Non-Small Cell Lung Cancer Across Lines of Therapy

  Clinical Lung Cancer · 2025-11-22

• Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non–Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy

  American Journal of Clinical Oncology · 2025-11-07 · 1 citations

• 513 Advanced analytics identify a differential immune response to CAN-2409+valacyclovir in non-squamous vs squamous NSCLC, linked to improved survival in patients with progressive ICI-refractory NSCLC

  Regular and Young Investigator Award Abstracts · 2025-11-01

• Clinician Perspectives on Digital and Computational Pathology: Clinical Benefits, Concerns, and Willingness to Adopt

  Diagnostics · 2025-10-07

• Development of a prognostic multiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first line immunotherapy

  Scientific Reports · 2025-10-03 · 2 citations

• MA10.02 CAN-2409 With Continued Immune Checkpoint Inhibitor (ICI) in Patients With Stage III/IV NSCLC With Inadequate Response to ICI

  Journal of Thoracic Oncology · 2025-10-01 · 1 citations

• P3.01.19 Gender Differences in Lung Cancer Diagnosis, Treatment Patterns and Outcomes: A Systematic Literature Review

  Journal of Thoracic Oncology · 2025-10-01

• 3208P 10-year outcomes from clinical trials of pembrolizumab (pembro) monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC)

  Annals of Oncology · 2025-09-01 · 2 citations

• 1856P Pembrolizumab (pembro) plus investigational agents as first-line therapy for treatment-naive PD-L1–positive advanced non–small-cell lung cancer (NSCLC): Results from KEYMAKER-U01 substudy 01B

  Annals of Oncology · 2025-09-01

• Toward Response-Adaptive Therapy in Locally Advanced NSCLC: Integrating ctDNA and Radiomics for Risk Stratification

  Cancer Discovery · 2025-08-04 · 4 citations

• Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer

  JAMA Network Open · 2025-07-15 · 19 citations